Novartis patient access scheme prompts wider Scots yes for Lucentis
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium, Scotland's health technology appraisal body, has expanded the potential market there for Novartis' eye drug Lucentis (ranibizumab) thanks to a list price discount. The news is not so good for Allergan, whose Ozurdex (dexamethasone implant) will likely face more competition from Lucentis now.